Technical Analysis for CERC - Cerecor Inc.

Cerecor, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company has a portfolio of clinical and preclinical compounds, such as CERC-301, CERC-501, and CERC-406. It develops CERC-301 that is in Phase II development stage as an oral, adjunctive antidepressant for the treatment of patients with major depressive disorder (MDD); CERC-501, which is in Phase II development, for co-occurring psychiatric and substance use disorders; and CERC-406 that is its preclinical lead candidate that inhibit catechol-O-methyltransferase within the brain, as well as anticipates developing CERC-406 for the treatment of residual cognitive impairment symptoms in patients with MDD. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor, Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.
Chemistry Biopharmaceutical Disorders Organic Chemistry Depression Major Depressive Disorder Antidepressants Piperidines Pyrrolidines Nmda Receptor Antagonists